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Stomach
Gastric cancer remains one of the 
most important malignant diseases with 
significant geographical differences in 
distribution. Annual mass screening for 
gastric cancer has been provided in 
Japan, Chile and Venezuela, aiming at 
detecting early gastric cancer. Japan 
introduced this screening programme in 
the 1960s using barium X-ray studies6. 
Barium X-ray study was regarded as a 
superior screening test out of four tests 
that were evaluated and studied, mainly 
photofluorography, serum pepsinogen 
levels, endoscopy and H. pylori 
antibody testing7. Sensitivity ranged 
between 60-80% and specificity ranged 
between 80-90%. Those that had an 
abnormal X-ray were offered upper 
endoscopy together with treatment. 
The 5 year survival rates that were 
achieved, as reported in 2008, were 
74-80% in the screened group versus 
46-56% in the non-screened group. 
Despite this programme, 40% of gastric 
cancers remain undetected and overall 
mortality was reduced by only 8%. This 
was mainly due to selection bias as 
the people who underwent screening 
were generally healthier than those 
who did not 6. Moreover, a cohort of 
24,000 individuals in Japan, classified 
into screened and unscreened groups 
and followed up for 40 months (1992 
– 1995), failed to show statistically 
significant reduction in mortality, once 
again due to selection bias8.
While gastric cancer screening is 
not practiced in the US, ASGE suggests 
carrying out surveillance endoscopy 
in patients with gastric premalignant 
conditions. Gastric adenomas have a 
high malignant potential and should be 
resected endoscopically or surgically 
with a surveillance endoscopy 1 year 
post-resection to assess the excision 
site, and every 3-5 years thereafter if 
the stomach is polyp-free. Patients 
with gastric intestinal metaplasia are 
not advised to undergo surveillance 
as there is lack of data in this field. 
On the other hand, patients with high 
grade dysplasia of the stomach should 
be considered for gastrectomy. Lastly, 
patients with FAP and tylosis should 
undergo surveillance programmes, 
while others with HNPCC should be 
considered for surveillance9.
Small Bowel
Tumors of the small bowel are 
quite rare and for this reason, there 
is a severe lack of guidelines on their 
management. To date, there are no 
screening programmes to detect 
small bowel tumors in asymptomatic 
individuals. Sporadic duodenal and 
ampullary adenomas are usually 
found incidentally during a routine 
OGD. These have been described to 
have malignant potential and ASGE 
has recommended surveillance post-
surgical or endoscopic resection. 
Surveillance for ampullary neoplasms 
vary from 1-6 months after the index 
procedure, followed by a repeat exam 
every 3-12 months for a period of at 
least 2 years. High grade dysplastic 
lesions require more intense monitoring. 
Formal recommendations regarding 
surveillance intervals for duodenal 
adenomas, on the other hand, could 
not be given due to the limited data 
available and should be decided on 
an individual basis. Moreover, data 
suggest that patients with duodenal or 
ampullary neoplasms are at a higher 
risk of colorectal polyps and neoplasia 
and should be offered screening 
colonoscopy10.
Colon
In 2002, CRC comprised 9.4% 
of the global cancer burden and its 
incidence is expected to increase as 
the world’s population is ageing. The 
risk of CRC increases with age and 
family history. It is rare below the age of 
50 but increases dramatically thereafter. 
CRC is the only gastrointestinal cancer 
where screening asymptomatic patients 
is practiced in many countries, with 
Malta joining them this October. CRC 
screening is however complex as there 
are multiple options and requires patient 
effort11. 
The two most common tests used for 
this screening are a stool-based test and 
an endoscopy or radiological-based test. 
Stool-based tests work on the basis that 
they detect blood shed by the tumor. The 
guaiac fecal occult blood test is the most 
common test used, however it requires 
dietary restrictions to avoid false positive 
results. Fecal immunochemical testing, 
on the other hand, obviates the need for 
these restrictions. Endoscopy, in the form 
of flexible sigmoidoscopy, is also widely 
practiced. This entails examination 
of the colon up to 60cm, is less time-
consuming than a colonoscopy, avoids 
sedation, bowel preparation is easier and 
morbidity is negligible if polypectomy 
is not required. Therapeutic procedures 
in the same examination can also be 
done. The disadvantage is that it misses 
right-sided lesions. Colonoscopy, being 
the “gold standard”, remains the test of 
choice when a screening test is positive, 
although it can also miss adenomas. 
Alternatively to endoscopy, in countries 
with limited resources, radiological tests 
such as DCBE or CT colonography 
remain a possibility. DCBE, although 
inferior to colonoscopy, may still detect 
50% of large polyps. CT colonography, 
on the other hand, has high sensitivity 
and specificity for large polyps but less 
so for small polyps. Disadvantages 
include the fact that flat lesions are 
frequently missed and patients are 
exposed to ionized radiation11.
Below, we shall see how screening 
is carried out differently in different 
countries. In the US, ACG recommends 
that quality colonoscopy is offered first, 
starting at age 50, and every 10 year 
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thereafter. Afro-Americans should 
start at age 45. Patients who decline 
colonoscopy should be offered an 
annual fecal immunochemistry test or 
a 5-yearly flexible sigmoidoscopy12. 
A completely different approach is 
adopted in UK. Individuals between the 
ages 60 – 69 are invited for screening 
every 2 years. FOBTs are sent out by 
post to their home and thereafter every 
2 years until age 69. This is done if the 
test is negative. Positive tests will then 
be followed up by a colonoscopy13. 
Scotland has a similar programme 
to that of the UK, however they have 
extended the age range from 50 – 74. 
A positive FOBT will be followed by a 
colonoscopy, whereas a negative FOBT 
will be followed up by a repeat FOBT 
every 2 years14. A recent meta-analysis 
of studies evaluating screening using 
FOBT estimated mortality reduction to 
be 15%15.
Recent data suggests that 5 
countries, namely UK, France, 
Australia, Belgium and Finland now 
offer national screening programmes, 
the most common screening 
modality being FOBT, followed up 
by endoscopy in positive tests. On 
the other hand, another 6 countries, 
namely US, Germany, New Zealand, 
Portugal, Switzerland and Spain, offer 
opportunistic screening where a test 
is offered to asymptomatic individuals 
who have seeked medical help for other 
reasons unrelated to CRC 15.
Patients with moderate or high risk of 
colorectal cancer
Patients who have a moderate or high 
risk of developing CRC are thus screened 
as part of a surveillance programme. 
Patients with moderate risk include 
patients with a positive family history 
of CRC, while patients with high risk 
include:
• Patients following detection of 
colorectal adenomas;
• Patients with inflammatory bowel 
disease;
• Patients following CRC resection;
• Patients with acromegaly;
• Patients with FAP, HNPCC, juvenile 
polyposis and peutz-jeghers 
syndrome;
• Patients with ureterosigmoidostomy.
It is worth mentioning some 
differences between US and UK 
regarding these programmes in the 
moderate risk group and the first 2 high 
risk groups:
Family History of Colorectal Cancer
Guidelines issued by the ACG in 2008 
recommend patients with a first-degree 
relative diagnosed with CRC at age ≥60 
years to have screening as the average 
risk population, i.e. colonoscopy every 
10 years, starting age 50. Patients with a 
first-degree relative diagnosed with CRC 
or advanced adenomas at age <60 years, 
or two first-degree relatives with CRC 
or advanced adenomas, should have a 
colonoscopy every 5 years starting at 
age 40, or 10 years younger than the age 
of diagnosis of the youngest affected 
relative12. On the other hand, BSG 
guidelines, issued in 2010, recommend 
patients with one affected first-degree 
relative age <50, to have a single 
colonoscopy at age 55 and average risk 
population recommendations thereafter. 
If the first-degree relative was diagnosed 
age ≥50, recommendations are the same 
as the average risk population16.
Patients with colorectal adenomas
2010 BSG guidelines risk-stratify such 
patients into low, intermediate or high 
risk depending on the number and size 
of adenomas detected. Surveillance is 
by means of colonoscopy every 5 years 
for low risk patients (1-2 adenomas, both 
<1cm), every 3 years for intermediate 
risk patients (3-4 small adenomas or at 
Colonoscopy, being the “gold standard”, 
remains the test of choice when 
a screening test is positive, although 
it can also miss adenomas
7
least one ≥1cm) and every year for high 
risk patients (≥5 small adenomas or 
≥3 at least ≥1cm)16. ASGE guidelines 
also stratify such patients in a similar 
way, the only difference being in the 
intermediate risk where the number of 
adenomas can be from 3 – 1017.
Patients with inflammatory bowel 
disease
CRC surveillance in this high 
risk group using colonoscopy and 
pancolonic dye-spray should start after 
10 years of colitic symptoms. Once 
again, BSG guidelines stratify patients 
in low, intermediate and high risk 
depending mainly on disease activity 
and extent and other risk factors such 
as FH of CRC or PSC. Low risk patients 
(no active disease) should repeat 
colonoscopy every 5 years, intermediate 
risk patients (mild active disease or FH) 
every 3 years and high risk patients 
(moderate/severe active disease or FH 
or PSC) every year16. On the other hand, 
ASGE recommends colonoscopy every 
one or two years beginning 8 – 10 years 
after disease onset in patients with 
extensive colitis. A case-control study 
showed a reduction in mortality in CRC 
in patients with ulcerative colitis using 
such surveillance programme17.
Liver, biliary tree and pancreas 
Surveillance for HCC is widely 
practiced across the world, however 
it is still controversial whether such 
management is beneficial or not, and 
which surveillance modality is best to 
use. In the US, the patients at risk of 
developing HCC, who are routinely 
surveilled, are
• Hepatitis B carriers: asian males 
over 40; asian females over 50; 
african/north american blacks; 
family history of HCC;
• All patients with cirrhosis.
The rationale for such surveillance 
is to detect small HCC lesions as 
these are amenable to resection 
or liver transplantation. AASLD, in 
2010, recommended screening these 
patients with just an ultrasound every 
6 months. They argue that AFP, having 
a sensitivity of 66% and a specificity of 
82%, is still inadequate as a screening 
test for HCC18.
In 2009, WGO suggested screening 
every 6-12 months in some patients, 
depending on the clinical scenario, 
whereas in high-risk patients, this 
should be done every 4-6 months. The 
test they recommend is an ultrasound, 
as the AFP still shows an imbalance 
between sensitivity and specificity. 
Moreover, combining both tests 
increased costs and false positive 
rates19.
On the other hand, BSG in 2003, 
recommended 6-monthly screening 
using both AFP and ultrasound to the 
same at-risk population mentioned 
above. They emphasized the use of 
high quality ultrasound with a dedicated 
equipment and operator expertise. 
Despite these recommendations, they 
also stated that there is not enough 
data to show long-term improvement 
in survival with this programme20.  
Following these guidelines, a new 
randomized controlled trial, in 2004, 
carried out in China, comparing 
surveillance versus no surveillance, 
showed a reduction in mortality by 37% 
when 6-monthly surveillance strategy 
using AFP and ultrasound was applied21.
As regards cholangiocarcinomas 
and pancreatic tumors, as of today, 
there are no screening programmes in 
asymptomatic patients.
Conclusion
Screening programmes are 
challenging and complex to organize. 
For these to be successful, multiple 
events have to occur hand-in-hand, 
starting from patient awareness and 
primary care physician recommendation, 
to patient acceptance, financial 
coverage, risk stratification, screening 
test, timely diagnosis, timely treatment 
to appropriate follow-up. If any of these 
is not of high quality, then screening 
will fail11. Although the above screening 
programmes are already reducing 
mortality, interventions should be 
aimed at improving uptake of patients 
and targeting noncompliance, mainly 
for CRC screening, as this is the most 
widely practiced15. 
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